Crohn’s disease
Prometheus Biosciences Inc. is active in inflammatory bowel disease research with a focus on Crohn’s disease, including clinical programs examining symptom control, endoscopic improvement, and clinical remission outcomes.
- Inflammatory bowel disease
- Crohn’s disease
- Endoscopic response
- Clinical remission
The sponsor’s work in this area reflects a therapeutic interest in disease activity reduction and intestinal healing.
Ulcerative colitis
The company also funds research in ulcerative colitis, with attention to induction therapy, tolerability, and the achievement of remission in patients with active colonic inflammation.
- Ulcerative colitis
- Induction therapy
- Safety and tolerability
- Remission
Its clinical activity in this field centers on therapies for chronic inflammatory disease of the colon.
Systemic sclerosis associated with interstitial lung disease
Prometheus Biosciences Inc. is involved in studies of systemic sclerosis associated with interstitial lung disease, a complex autoimmune condition marked by fibrotic lung involvement and declining respiratory function.
- Systemic sclerosis
- Interstitial lung disease
- Autoimmune disease
- Pulmonary fibrosis
Research in this area reflects interest in preserving forced vital capacity and addressing organ-threatening manifestations of connective tissue disease.
Immune-mediated disease
The sponsor’s trial portfolio is concentrated in immune-mediated inflammatory disorders, with overlapping interest in gastrointestinal and rheumatologic disease domains.
- Immune-mediated inflammation
- Gastrointestinal disease
- Rheumatologic disease
- Fibrotic disease
This therapeutic scope spans chronic conditions where immune dysregulation drives tissue injury and progressive clinical burden.
